NASDAQ:NGEN NervGen Pharma (NGEN) Stock Price, News & Analysis $2.13 -0.06 (-2.74%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$2.14 +0.01 (+0.47%) As of 09/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC FilingsShort Interest About NervGen Pharma Stock (NASDAQ:NGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$2.12▼$2.2750-Day Range$1.59▼$2.3452-Week Range$1.58▼$6.30Volume365,094 shsAverage Volume615,965 shsMarket Capitalization$171.74 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingModerate Buy Company Overview NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments. The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings. NervGen’s development activities center on progressing NVG-291 and related research through clinical trials to assess safety, tolerability and potential to improve functional outcomes for patients with neurological damage. NervGen is publicly traded on the NASDAQ under the ticker NGEN and operates as a research-driven biopharmaceutical organization. The company conducts clinical development activities and research collaborations to support its programs and to advance regulatory development pathways for its therapeutics. As a clinical-stage company, NervGen’s prospects are tied to the progress and results of its clinical trials and development partnerships. Its work is representative of the broader effort in biotechnology to develop novel regenerative treatments for conditions with significant unmet medical need in neurology. Investors and stakeholders typically follow clinical milestones and regulatory updates when evaluating the company’s progress. AI Generated. May Contain Errors. Read More NervGen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreNGEN MarketRank™: NervGen Pharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 676th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingNervGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNervGen Pharma has a consensus price target of $14.00, representing about 557.3% upside from its current price of $2.13.Amount of Analyst CoverageNervGen Pharma has only been the subject of 2 research reports in the past 90 days.Read more about NervGen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NervGen Pharma are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NervGen Pharma is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NervGen Pharma is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNervGen Pharma has a P/B Ratio of 71.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.62% of the float of NervGen Pharma has been sold short.Short Interest Ratio / Days to CoverNervGen Pharma has a short interest ratio ("days to cover") of 13.83, which indicates bearish sentiment.Change versus previous monthShort interest in NervGen Pharma has recently decreased by 1.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNervGen Pharma does not currently pay a dividend.Dividend GrowthNervGen Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NervGen Pharma this week, compared to 3 articles on an average week.Search Interest2 people have searched for NGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added NervGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NervGen Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of NervGen Pharma is held by insiders.Percentage Held by InstitutionsNervGen Pharma has minimal institutional ownership at this time.Read more about NervGen Pharma's insider trading history. Receive NGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGEN Stock News HeadlinesNervGen to Host Inaugural R&D Day on September 30, 2026September 9 at 7:30 AM | globenewswire.comBrokerages Set NervGen Pharma (NASDAQ:NGEN) PT at $14.00August 30, 2026 | americanbankingnews.comThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin. It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace. Most Wall Street analysts have not caught on yet, but a major milestone could change that soon. | Freedom Financial (Ad)NervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | finanznachrichten.deNervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash PositionAugust 13, 2026 | tipranks.comNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comNervGen Pharma Corp. : NGENJuly 13, 2026 | 247wallst.comNervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink PartnersJuly 2, 2026 | tipranks.comSee More Headlines NGEN Stock Analysis - Frequently Asked Questions How have NGEN shares performed this year? NervGen Pharma's stock was trading at $3.85 on April 27, 2026. Since then, NGEN stock has decreased by 44.7% and is now trading at $2.13. How were NervGen Pharma's earnings last quarter? NervGen Pharma (NASDAQ:NGEN) released its earnings results on Thursday, August, 13th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.28. Who are NervGen Pharma's major shareholders? Top institutional investors of NervGen Pharma include Empery Asset Management LP (4.96%), Stonepine Capital Management LLC (0.34%), Bank of America Corp DE (0.23%) and AXQ Capital LP (0.05%). How do I buy shares of NervGen Pharma? Shares of NGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/09/2026Status update9/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NGEN CIK1751912 Webnervgen.com Phone(604) 722-5361FaxN/AEmployeesN/AYear Founded2017Price Target and Rating Average Price Target for NervGen Pharma$14.00 High Price Target$18.00 Low Price Target$10.00 Potential Upside/Downside+557.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,259.82% Return on Assets-199.79% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book71.00Miscellaneous Outstanding Shares80,630,000Free Float75,954,000Market Cap$171.74 million OptionableN/A BetaN/A Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NGEN) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
